Symbols

CASI(Delisted)

CASI Pharmaceuticals·NASDAQ

--(--)

CASI fundamentals

CASI Q3 2025 Earnings

CASI Pharmaceuticals (CASI) released its earnings on Nov 14, 2025: revenue was 3.08M (YoY -60.54%), beat estimates; EPS was -0.68 (YoY -23.64%), missed estimates.

Revenue / YoY

3.08M

-60.54%

EPS / YoY

-0.68

-23.64%

Report date

Nov 14, 2025

Earnings

EPS

Revenue

Revenue & Expenses

CASI has released its 2025 Q3 earnings report, with revenue of 3.08M, reflecting a YoY change of -60.54%, and net profit of -10.88M, showing a YoY change of -29.64%. The Sankey diagram below clearly presents CASI's revenue sources and cost distribution.

Key Indicators

CASI Pharmaceuticals (CASI) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

CASI Pharmaceuticals (CASI)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

CASI Pharmaceuticals (CASI)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

CASI Pharmaceuticals (CASI)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown

Revenue Breakdown

Where does CASI Pharmaceuticals (CASI) generate its revenue? Explore its key revenue streams and top earning regions.

By Business

Data source:

By Region

Data source:

Dividend

Track CASI Pharmaceuticals (CASI) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History

Payout Ratio

Dividend Yield

You can ask Aime

No Data